1. Impact of socioeconomic status in patients hospitalised for COVID-19 in the Greater Paris area.
- Author
-
Sesé L, Nguyen Y, Giroux Leprieur E, Annesi-Maesano I, Cavalin C, Goupil de Bouillé J, Demestier L, Dhote R, Tandjaoui-Lambiotte Y, Bauvois A, Pépin M, Curac S, Beaune S, Duchemann B, and Nunes H
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Paris epidemiology, Prospective Studies, Severity of Illness Index, COVID-19 epidemiology, Hospitalization, Social Class
- Abstract
Competing Interests: Conflict of interest: L. Sesé reports personal fees and non-financial support from Roche/Genentech (consultant and congress), and non-financial support from Boehringer Ingelheim (congress), outside the submitted work. Conflict of interest: Y. Nguyen has nothing to disclose. Conflict of interest: E. Giroux Leprieur reports grants, personal fees and non-financial support from AstraZeneca, Bristol-Myers-Squibb and Roche, personal fees and non-financial support from Boehringer Ingelheim, MSD and Novartis, and non-financial support from Takeda, outside the submitted work. Conflict of interest: I. Annesi-Maesano has nothing to disclose. Conflict of interest: C. Cavalin has nothing to disclose. Conflict of interest: J. Goupil de Bouillé has nothing to disclose. Conflict of interest: L. Demestier has nothing to disclose. Conflict of interest: R. Dhote has nothing to disclose. Conflict of interest: Y. Tandjaoui-Lambiotte has nothing to disclose. Conflict of interest: A. Bauvois has nothing to disclose. Conflict of interest: M. Pépin has nothing to disclose. Conflict of interest: S. Curac has nothing to disclose. Conflict of interest: S. Beaune has nothing to disclose. Conflict of interest: B. Duchemann reports non-financial support from Roche, Oxyvie, Pfizer and AstraZeneca, and personal fees from MSD, outside the submitted work. Conflict of interest: H. Nunes reports grants and personal fees from Roche/Genentech (consultant and research support fees) and Boehringer Ingelheim (consultant and research support fees), personal fees from Galapagos (expert for clinical endpoint committee), other from Sanofi (investigator of clinical trial), Gilead (investigator of clinical trial), Novartis (investigator of clinical trial) and Galecto Biotech AB (investigator of clinical trial), during the conduct of the study; personal fees from Actelion Pharmaceuticals (board expert for clinical trial), outside the submitted work.
- Published
- 2020
- Full Text
- View/download PDF